Mt nghin cu nm 2006 ch ra s kt hp ny c th gim triu chng vim khp
Incretin-based drugs work by restoring that signal pharmacologically
In most cases where menstrual changes occur during weight loss, these settle as weight stabilises and the body adapts to its new metabolic state
Retatrutide started low and stepped up monthly the way the trial escalation tables do, sitting in the mid single-digit milligram range once I was comfortable
Merck's MK-0893, a small-molecule GCGR antagonist, reached Phase 2b in type 2 diabetes and showed meaningful HbA1c reductions - alongside dose-dependent LDL cholesterol increases, transaminase elevations, and modest weight gain that together made the molecule untenable as a chronic medicine

You should discuss cancer concerns with your GP or specialist before starting a GLP-1 medicine if you have: Personal history of any cancer, particularly thyroid or pancreatic malignancies Family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Previous episodes of pancreatitis Unexplained symptoms such as persistent abdominal pain, neck lumps, or difficulty swallowing Anxiety about cancer risk that may affect medicine adherence During treatment with a GLP-1 medicine, contact your healthcare provider promptly if you develop: A lump or swelling in the neck Persistent hoarseness or voice changes Difficulty swallowing or breathing Severe, persistent abdominal pain, especially if radiating to the back (seek urgent medical help via NHS 111 or A&E if severe) Unexpected or disproportionate weight loss relative to your dose and treatment plan, especially with other concerning symptoms Any other worrying symptoms It is important to maintain perspective: the proven cardiovascular benefits of GLP-1 medicines in reducing heart attack, stroke, and cardiovascular death substantially outweigh theoretical cancer concerns for most patients
